According to the ARRS American Journal of Roentgenology (AJR), contrast-enhanced mammography (CEM) may be a useful alternative test for neoadjuvant therapy (NAT) response assessment in patients with breast cancer who are ...
Jun 22, 2022
0
2
Men with Stage IV breast cancer and known estrogen (ER) and progesterone receptor (PR) status benefit from surgical intervention and from trimodal therapy (systemic therapy, surgery, and radiation), according to a study presented ...
Oct 24, 2021
0
3
(HealthDay)—For patients with stage II pancreatic cancer, attempted surgery with margin-positive resection may offer survival benefit over chemotherapy alone, according to a study published online March 26 in the Journal ...
Apr 22, 2021
0
2
According to an open-access Editor's Choice article in ARRS' American Journal of Roentgenology (AJR), post-neoadjuvant therapy (NAT) changes in metabolic metrics from PET/MRI and morphologic metrics from CT were associated ...
Dec 9, 2020
0
3
Immune therapy added to chemotherapy improves pathological complete response in patients with early triple negative breast cancer, according to late breaking results from the KEYNOTE-522 trial presented at the ESMO Congress ...
Sep 29, 2019
0
4
A new clinical guideline from the American Society for Radiation Oncology (ASTRO) provides recommendations on the use of radiation therapy to treat patients diagnosed with pancreatic cancer, including when radiation treatments ...
Sep 4, 2019
0
2
(HealthDay)—Neoadjuvant administration of programmed cell death protein 1 (PD-1) blockade seems to enhance local and systemic antitumor immune response in glioblastoma, according to a study published online Feb. 11 in Nature ...
Feb 13, 2019
0
2
Neoadjuvant endocrine therapy - designed to reduce the size of breast tumors before surgical removal - appears to be as effective as neoadjuvant chemotherapy for patients with localized, estrogen-receptor (ER)-positive breast ...
Nov 9, 2016
0
4
According to ARRS' American Journal of Roentgenology (AJR), new suspicious findings occurred in 5.5% of breast MRI examinations performed to monitor response to neoadjuvant therapy; none of these new lesions were malignant.
Jan 14, 2021
0
5
For patients with operable non-small cell lung cancer (NSCLC), pre-surgical "neoadjuvant" treatment with an immune checkpoint inhibitor was well tolerated and, in many cases, caused significant tumor cell death in a large, ...
May 31, 2019
0
0
